Board of Directors

Ron Renaud has more than 25 years of experience in evaluating, building, and leading biotechnology companies, with deep expertise in executive leadership, finance, and operations. He currently serves as Kailera’s President and Chief Executive Officer. Prior to joining Kailera, Mr. Renaud served as Cerevel Therapeutics’ President and Chief Executive Officer, where he guided the company through significant milestones, culminating in its acquisition by AbbVie in 2024. Previously, he served as a partner at Bain Capital Life Sciences. Before Bain, he led Translate Bio as Chairman and Chief Executive Officer from 2014 until the close of its acquisition by Sanofi in 2021. During his tenure, he transformed the company from a start-up platform into a leading mRNA company. Mr. Renaud was at Idenix Pharmaceuticals from 2007 through 2014, where he served as Chief Financial Officer, Chief Business Officer and finally, President and Chief Executive Officer. Under his leadership as CEO, the company streamlined operations, increased employee engagement, and re-focused research and development supported by significant capital raises, culminating in the company’s acquisition by Merck.

Earlier in his career, Mr. Renaud was a biotechnology equity research analyst at J.P. Morgan, Schwab Soundview and Bear Stearns. He also spent more than five years at Amgen, where he held positions in clinical research, investor relations and finance. He earned his bachelor’s degree from St. Anselm College and an MBA from the Marshall School of Business at the University of Southern California.